An observational study in Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm and Malignant Genitourinary System Neoplasm, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 104 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Wake Forest University Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 22nd largest by planned enrollment of the 64 observational ones that give a count, is one of 15 that started in 2026, is one of 64 observational ones, reaches primary completion later than 41 of the 113 other live ones, and was the 297th registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18–99
Orlando Health, Inc. · Sites in United States
Ages 18–100
Northwestern University · Sites in United States
Ages 18+
BigHat Biosciences, Inc. · Sites in United States
Ages 18+
Genmab · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
316 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 96 · Phase 2 82 · Phase 3 12 · Phase 4 4
First in 1995; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 168 observational studies indexed under Gastrointestinal Neoplasms.
Median enrollment 60 across the 245 interventional studies, 172 across the 64 observational. Of the 182 that completed or were terminated, 68 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 316 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Wake Forest University Health Sciences has 5 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Gastrointestinal Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511037University of California, IrvinePhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | 2026-11-30 |
| NCT05318027Abramson Cancer Center at Penn MedicineChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT06569693University of MiamiDyadic Sleep Study | 2026-12-01 |
| NCT06134687Baylor College of MedicineNovel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection | 2026-12-04 |
Add all 40 to your calendar (.ics) → With an account.
Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).
PRIMARY OBJECTIVE:
I. To evaluate self-reported utilization of guideline concordant extended venous thromboembolism (VTE) prophylaxis (ePPx) following abdominopelvic cancer surgery within a sample of surgeons practicing within NCORP based on the Part 1 surgeon survey.
SECONDARY OBJECTIVES:
I. Evaluate site factors (e.g., proportion of publicly insured patients, proportion of Black patients, presence of a medical school, NCI designation) and surgeon factors (e.g., fellowship training, years in practice) associated with surgeon self-reported guideline concordant ePPx utilization (Part 1).
II. Conduct semi-structured interviews among a subset of surgeons and surgical APPs to assess: 1) Barriers/facilitators toward ePPx after cancer surgery and 2) Acceptability of clinical decision support tools to support VTE prophylaxis prescribing (Part 2).
III. Extract EHR data from select practices to assess the feasibility of query-based electronic health record (EHR) data extraction for identification of (i) patients undergoing cancer surgery, and (ii) prescription of guideline concordant ePPx among eligible patients (Part 3).
OUTLINE: This is an observational study.
PART 1: Surgeons and APPs complete a survey on study. After completion of surgeon or APP survey, site contact person or Cancer Care Delivery Research (CCDR) lead complete site surveys on study.
PART 2: A subset of surgeons and APPs from part 1 complete a semi-structured interview on study.
PART 3: Site contact person or CCDR lead complete a survey to identify a EHR Report Specialist on study. EHR Report Specialist performs an EHR Data Extraction and provides feedback on the process in a survey.
This multi-part study employs a mixed-methods design to evaluate the utilization of ePPx following abdominopelvic cancer surgery within the NCORP network. Part 1 involves a cross-sectional survey of at least 100 surgeons/APPs from at least 25 NCORP sites to evaluate practice patterns related to ePPx. Part 2 utilizes purposive sampling to conduct interviews with 11-25 surgeons/APPs from Part 1 to obtain granular detail about barriers and facilitators to guideline concordant utilization of ePPx. Part 3 will purposively sample 6 practices identified in Part 1 to evaluate the feasibility of EHR queries to assess ePPx utilization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
SURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:
* Any surgeon performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgeons do not need to be involved in research or have a Cancer Therapy Evaluation Program Identification (CTEP ID) to participate in this study
SURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:
* APPs providing postoperative care to patients operated by surgeons performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgical APPs do not need to be involved in research or have a CTEP ID to participate in this study
SURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:
* Must have completed the STOP-VTE Survey - Surgeon electronically (preferred) or on paper and have it transferred to Research Electronic Data Capture (REDCap) by the contact person(s)
SURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:
* Must have completed the STOP-VTE Survey - APP electronically (preferred) or on paper and have it transferred to REDCap by the contact person(s)
SITE ELIGIBILITY PART 1-SITE ENROLLMENT IN OPEN:
* Have at least one eligible surgeon or surgical APP who completed the STOP-VTE Survey - Surgeon/APP
Exclusion Criteria:
Surgeons and APPs complete a survey on study. After completion of surgeon or APP survey, site contact person or CCDR lead complete site surveys on study.
Other: Non-Interventional Study
Subset of surgeons and APPs from Part 1 complete a semi-structured interview on study.
Other: Non-Interventional Study
Site contact person or CCDR lead complete a survey to identify a EHR Report Specialist on study. EHR Report Specialist performs an EHR Data Extraction and provides feedback on the process in a survey.
Other: Non-Interventional Study
Non-interventional study
Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Self-reported utilization of guideline concordant ePPx for surgeons (Part 1)
Will apply only to surgeons completing the Part 1 survey. Will be defined as answering "Yes, all cases or almost all cases" on the survey question asking about prescription of ePPx after discharge. The proportion of surgeons self-reporting utilization of guideline concordant ePPx will be estimated and reported along with an exact 95% confidence interval.
Time frame: After 1 year from start of Part 1
Self-reported utilization of guideline concordant ePPx for surgeons within strata defined by site and surgeon factors (Part 1)
Self reported utilization as defined above for the primary outcome measure will be reported within strata defined by: * Site factors (e.g., proportion of publicly insured patients, proportion of Black patients, presence of a medical school, NCI designation) * Surgeon factors (e.g., fellowship training, years in practice)
Time frame: After 1 year from start of Part 1
Barriers and facilitators toward ePPx after cancer surgery, and acceptability of clinical decision support tools to support VTE prophylaxis prescribing (Part 2)
Themes from qualitative interviews by surgeons and APPs
Time frame: After 6 months from start of Part 2
Feasibility (i.e., proportion of practices able to provide data) of EHR queries from selected practices to inform future trial (Part 3)
Considered feasible if at least 4 of the 6 practices who agreed to participate are able to provide data on both patients undergoing cancer surgery and prescription of guideline concordant ePPx among eligible patients
Time frame: After 6 months from start of Part 3
Showing the first 100 of 104 sites across 2 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.
Time frame: 6 months after publication for a 2 year duration
Access criteria: upon request to NCORP@wakehealth.edu
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.
Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's planned 13 months is below that.
Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →